New targeted drug shows promise against tough cancers
NCT ID NCT05005234
First seen Nov 17, 2025 · Last updated May 22, 2026 · Updated 26 times
Summary
This study tested a new drug called GFH925 in 334 adults with advanced solid tumors that have a specific gene change (KRAS G12C). The goal was to check the drug's safety and how well it shrinks tumors in cancers like lung and colorectal cancer. The drug is taken as a pill and targets the faulty protein made by the gene change.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12C are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.